Lupin will report its June-quarter earnings on Wednesday and analysts expect the drugmaker to report a good set of results. \tFor Lupin, revenue growth is seen at 15 percent, margins around 18 percent and profit growth at 37 percent, aided by what would be a low base. Last time around, the profit was down 40 percent and revenue was absolutely flat. \tIn the US business – one should watch out for a couple of things. For example, they lost exclusivity on Ranexa. And separately, one should also watch out for contribution from drugs which are from their gynaecology portfolio. \tOverall commentary with regards to what is happening on the regulatory front would be very important for Lupin.